The European Medicines Agency (EMA) is investigating the risk of developing thromboembolism with Janssen’s preparations, while continuously analyzing three other vehicles of the covid-19, between them and the Russian Sputnik, to be used in a European Union (EU) by the use of AstraZeneca for the thrombus risk.
The Human Pharmacists Committee (CHMP) has launched a real-time analysis process of the Novavax vaccine vaccine from the 3rd of February; the CureVac German from February 12, and the Russian Sputnik V from March 4, but no one has a calendar to file for the application to apply for a conditional license from the UE, as well as from Pfizer / BioNtech, Moderna , AstraZeneca and Janssen.
The EMA responded on 11 March to the use of the Johnson & Johnson vaccine, which is not being used in the European Union (EU) to debit retrospective dose delivery by the laboratory.
The regulator confirmed that it is also investigating this evacuation, as it did with AstraZeneca, over four cases of severe posterior coagulation coagulation during evacuation.
The EMA analyzes data on these four cases of unusual blood clotting with plaques in patients who have received this vaccine in advance, one of them during the clinical trial and three during the use of Janssen in United States, by those who died .
Leave the full note in our print version subscribe to our AQUÍ digital version.
You can find more content like this in our social networks of Facebook, Twitter e Instagram.